Latest news with #JuvenileIdiopathicArthritis
Daily Record
31-07-2025
- Health
- Daily Record
Two relatives of young girl with Juvenile Idiopathic Arthritis walk East Highland Way for charity
Little Addison Hutchison, two, was diagnosed with JIA when she was just 14-months-old. Two intrepid relatives of a young Lanarkshire girl who suffers from Juvenile Idiopathic Arthritis (JIA) embarked on a testing trek to raise funds for charity. Little Addison Hutchison, two, of Hamilton, was diagnosed with JIA when she was just 14-months-old. The youngster is bravely battling the condition, which causes joint pain and inflammation in the hands, knees, ankles, elbows and/or wrists, and inspired her dad Alan's uncle Jim and Jim's uncle Hugh, both from Airdrie, to walk the East Highland Way in aid of the Scottish Network for Arthritis in Children (SNAC). Addison's gran Sandra Hutchison told Lanarkshire Live: "Addison is such a brave wee girl and Jim and Hugh wanted to support a charity doing its bit to tackle JIA. "Addison has to take methotrexate every week and amgevita every fortnight. "The colder weather can be a challenging time for her due to the autoimmune disease. "She had to have steroid injections to help make her walk at first but soon found her feet. "And Addison loves dancing , horse riding and swimming. She's a wee fighter and tries hard to not to get down." Jim, 52, and Hugh, 76, raised a fantastic £1410 for the SNAC charity from a walk that wasn't without its challenges. Sandra explained: "The first couple of days were tough for Jim and Hugh as it was during the heatwave, so they were really put through their paces. "But they completed the 86-mile route in an impressive four-and-a-half days and collected £1410 for SNAC, who provide information, practical help and emotional support for children with juvenile idiopathic arthritis and their families. "The whole family wishes to congratulate, and thank, Jim and Hugh for completing the East Highland Way walk and raising so much for the charity; and we would all also like to thank everyone who donated to the final total for their kindness and support." *Don't miss the latest headlines from around Lanarkshire. Sign up to our newsletters here. And did you know Lanarkshire Live had its own app? Download yours for free here.
Globe and Mail
29-07-2025
- Health
- Globe and Mail
Juvenile Idiopathic Arthritis Therapeutic Landscape Shifts as Biologics and JAK Inhibitors Drive Significant Growth
The Juvenile Idiopathic Arthritis market is entering a period of robust expansion, underpinned by increasing awareness, advances in diagnostics, and a wave of novel therapeutics from leading pharmaceutical and biotech companies, such as Novartis, Roche (Chugai Pharmaceutical), AbbVie, AstraZeneca, Pfizer, Eli Lilly, and Incyte Corporation. DelveInsight's report, ' Juvenile Idiopathic Arthritis Market Insight, Epidemiology and Market Forecast – 2032,' reveals that the Juvenile Idiopathic Arthritis therapeutic landscape across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom and Japan is growing noticeably, underpinned by advancements in targeted therapies (such as biologics and JAK inhibitors), increased investment in research and development, and the introduction of innovative diagnostic tools. The United States holds the largest market share in terms of both revenue and patient pool across 7MM, primarily due to better diagnosis, the highest pharmaceutical spending per capita globally, and significant drug development efforts with the presence of major Juvenile Idiopathic Arthritis drug companies in the country. Download the Juvenile Idiopathic Arthritis Market report to understand market dynamics and treatment landscape trends. DelveInsight's epidemiological modelling underscores that Juvenile Idiopathic Arthritis, the most common chronic rheumatic disease of childhood, continues to present significant clinical and economic challenges across the 7MM. Studies show that females are generally more affected than males by Juvenile Idiopathic Arthritis, although this trend varies depending on the specific subtype, with enthesitis-related JIA notably showing a male predominance. Furthermore, the DelveInsight report details country-specific diagnosed Juvenile Idiopathic Arthritis patient pools from 2019 to 2032 and highlights a steady upward trend driven by heightened diagnostic vigilance and improved registry coverage. Notably, the United States captures the largest share of identified Juvenile Idiopathic Arthritis cases, whereas Germany leads within the European countries, reflecting regional variations in paediatric rheumatology infrastructure and reporting mechanisms. Discover evolving trends in the Juvenile Idiopathic Arthritis patient pool forecasts @ Juvenile Idiopathic Arthritis Epidemiology Analysis. The Juvenile Idiopathic Arthritis treatment landscape has evolved considerably, transitioning from conventional non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) to sophisticated biologic and targeted synthetic agents that inhibit key inflammatory pathways. Although methotrexate retains a central role as an anchor DMARD, an expanding class of tumour necrosis factor (TNF) inhibitors, interleukin (IL) blockers and Janus kinase (JAK) inhibitors has reshaped the Juvenile Idiopathic Arthritis therapeutic paradigm, offering clinicians greater flexibility for refractory disease. According to the DelveInsight report, the Juvenile Idiopathic Arthritis therapies pipeline shows promising development activity. New developments in Juvenile Idiopathic Arthritis therapies are focused on targeted approaches, particularly JAK inhibitors. Tofacitinib and baricitinib are two JAK inhibitors that have been approved for use in specific Juvenile Idiopathic Arthritis subtypes, primarily in cases where patients haven't responded well to other treatments like TNF inhibitors. Baricitinib, for instance, has shown efficacy in patients with polyarticular Juvenile Idiopathic Arthritis, extended oligoarticular Juvenile Idiopathic Arthritis, enthesitis-related arthritis, and psoriatic Juvenile Idiopathic Arthritis aged 2 to 18 years. Tofacitinib has also been shown to be effective in patients with polyarticular course Juvenile Idiopathic Arthritis. Furthermore, the competitive intelligence section of the report highlights novel agents targeting cytokine signalling beyond TNF and IL-6, as well as next-generation oral molecules designed to optimise patient adherence. Robust evaluation of launch timelines, annual cost of therapy, and forecast clinical differentiation suggests a wave of innovative entrants that could meaningfully expand the Juvenile Idiopathic Arthritis drugs in the coming decade. Dive Deeper into the evolving treatment landscape @ Juvenile Idiopathic Arthritis Emerging Therapies. Key opinion leader insights collected through primary research validate these trends and pinpoint persistent gaps such as limited treatment options for systemic Juvenile Idiopathic Arthritis flares, glucocorticoid sparing strategies, and long-term safety surveillance in growing children. KOLs also emphasise the need for biomarkers that can guide personalised therapeutic sequencing and predict disease trajectory, a frontier that remains largely unaddressed despite significant scientific advances. Addressing these challenges offers significant opportunities for innovative biotech and pharma entities to carve out competitive advantages in an increasingly crowded market landscape. Looking ahead, the Juvenile Idiopathic Arthritis market is poised to benefit from deeper understanding of disease pathogenesis, breakthrough device-assisted drug-delivery platforms and collaborative research networks that accelerate paediatric trial recruitment. While significant strides have been made, continued innovation in immune-modulation, tolerability optimisation and health-equity initiatives will be essential to fully meet the unmet needs of this vulnerable patient population. Stakeholders who leverage DelveInsight's granular insights stand to capitalise on the forthcoming wave of therapeutic progress and capture value in a market primed for transformative growth through 2032. Table of Contents 1. Key Insights 2. Executive Summary of Juvenile Idiopathic Arthritis 3. Competitive Intelligence Analysis for Juvenile Idiopathic Arthritis 4. Juvenile Idiopathic Arthritis Market Overview at a Glance 5. Juvenile Idiopathic Arthritis: Disease Background and Overview 6. Juvenile Idiopathic Arthritis Patient Journey 7. Juvenile Idiopathic Arthritis Epidemiology and Patient Population 8. Treatment Algorithm, Current Treatment, and Medical Practices 9. Juvenile Idiopathic Arthritis Unmet Needs 10. Key Endpoints of Juvenile Idiopathic Arthritis Treatment 11. Juvenile Idiopathic Arthritis Marketed Products 12. Juvenile Idiopathic Arthritis Emerging Therapies 13. Juvenile Idiopathic Arthritis: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Access and Reimbursement Overview of Juvenile Idiopathic Arthritis 17. KOL Views 18. Juvenile Idiopathic Arthritis Market Drivers 19. Juvenile Idiopathic Arthritis Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight Related Reports Juvenile Idiopathic Arthritis Pipeline Insight Juvenile Idiopathic Arthritis pipeline insight provides comprehensive insights about the Juvenile Idiopathic Arthritis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Juvenile Idiopathic Arthritis companies, including Novartis, Roche, AbbVie, AstraZeneca, Pfizer, Eli Lilly, and Incyte Corporation, among others. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Daily Mirror
10-05-2025
- Health
- Daily Mirror
'My one-year-old has condition common in old people - we couldn't believe it'
While arthritis is more commonly known to affect older people, it can occur in youngsters too. We speak to the father of one of 10,000 UK children living with the condition When Stuart Harley was looking after his young son Rox, he noticed that one of his ankles suddenly became inflamed. "Rox had walked early, he was always on the move," said the project engineer. "Then when he was about one and half, we noticed his left ankle was swollen. He went on to develop a limp." Stuart and Rox's mother, who are not together, sought medical attention and doctors initially thought the cause could be an infection. "At first we wondered if he'd twisted the ankle and being so tiny, didn't know to rest it," said Stuart. "We sought help and Rox was given antibiotics for a possible infection early on but his ankle flared up once more. We went back and forth with appointments." With blood tests ruling out more common causes and the problem not improving, Rox was referred to a rheumatologist, a doctor specialising in diseases affecting the joints, muscles, bones, and connective tissues. To Stuart's astonishment, his young son was diagnosed with arthritis. "I was so shocked," he said. "Rox was so little so it's not the first thing you think of." Juvenile Idiopathic Arthritis or JIA, affects 10,000 children in the UK and causes joint pain, swelling and stiffness. Limping and fevers are among the symptoms to look out for. JIA is an autoimmune disease which sees the body's immune system mistakenly attack healthy tissues, particularly the joints. The exact causes for developing arthritis under the age of 16 are unknown but some researchers believe genetics can play a part, making some children more susceptible to the condition than others. Following his diagnosis, Rox was put under anaesthetic and given cortisone injections in his ankle, providing much-needed, temporary pain relief. Now three, he has weekly injections of Methotrexate, which slows down the body's immune system and helps to reduce swelling and and monthly infusions of infliximab, a medicine used to treat inflammation. "I'm trying not to get upset but it was heartbreaking," said Stuart of seeing his son put to sleep. "Rox is doing so well now but it was so, so hard." There is no single test for JIA, with doctors diagnosing it using a process of elimination. In February, a national report into the quality of care for children and young adults suffering from the disease was released and the conclusion was a swift diagnosis was based 'on luck'. Early diagnosis is crucial for preventing joint damage, managing symptoms and achieving remission but the report, commissioned by the Healthcare Quality Improvement Partnership, highlighted a lack of awareness among health professionals of the condition. The National Confidential Enquiry into Patient Outcome and Deaths' publication found fewer than half of patients who would go on to be diagnosed with JIA were seen within the recommended 10 weeks from the onset of symptoms. The longest a patient had to wait was 175 weeks. In more than a third of cases looked at referrals were sent to the wrong specialities, with undiagnosed patients frequently seen to 'bounce' between primary care and various specialties and then back to primary care before being seen by rheumatology services. "We met the family of a four year old girl undergoing the same treatment, it had taken them two years to be given a diagnosis," said Stuart. "I really wanted to raise awareness, I felt I needed to do something." Stuart completed this year London Marathon's in 4 hour and 24 minutes, raising more than £3,000 for leading charity Versus Arthritis. "I wanted to show Rox anything was possible," he said. "Arthritis is part of his life now, he has his medication and he gets tired." Many young sufferers of the condition can experience good outcomes, with their arthritis going into remission meaning symptoms significantly reduce or even disappear altogether. For others, further health problems can occur including slow growth, osteoporosis or problems with the heart or kidneys. "I get a bit scared, I just want Rox's joints to be ok and for him to be able to live a normal life, free from pain," said Stuart, from Stirling in Scotland. "I'd love him to run the London Marathon himself one day." Versus Arthritis offers help to young sufferers and their families - visit their support page here. To donate to Stuart's London Marathon fundraising for the charity, visit his Just Giving page.
